GHZ339 for Eczema

Recruiting at 10 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Novartis Pharmaceuticals

Disqualifiers: Uncontrolled diabetes, hypertension, asthma, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

224 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Are You a Good Fit for This Trial?

This trial is for people with moderate to severe atopic dermatitis (AD), commonly known as eczema, that's been diagnosed for at least a year. Participants must be able to understand and sign the informed consent form.

Inclusion Criteria

I have moderate to severe atopic dermatitis.

I am willing and able to sign the consent form.

I have been diagnosed with Alzheimer's disease for at least 1 year.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Period 1

Participants receive either GHZ339 at various doses or placebo

16 weeks

Regular visits as per protocol

Treatment Period 2

Participants receive GHZ339 at assigned doses based on Treatment Period 1

16 weeks

Regular visits as per protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• GHZ339

Trial Overview The study is testing GHZ339, an experimental compound, against a placebo to see which one better improves symptoms of AD. It's designed to compare results between these two groups over time.

How Is the Trial Designed?

Group I: GHZ339 Dose D Experimental Treatment 1 Intervention

Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2

Group II: GHZ339 Dose C Experimental Treatment 1 Intervention

Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2

Group III: GHZ339 Dose B Experimental Treatment 1 Intervention

Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2

Group IV: GHZ339 Dose A Experimental Treatment 1 Intervention

Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2

Group V: Placebo Placebo Group 2 Interventions

Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals

Lead Sponsor

Trials

2,963

Recruited

4,275,000+

Founded

1996

Headquarters

Basel, Switzerland

Known For

Precision medicine

Top Products

Gleevec, Cosentyx, Entresto, Kisqali

Dr. Vas Narasimhan

Novartis Pharmaceuticals

Chief Executive Officer since 2018

MD from Harvard Medical School

Dr. Shreeram Aradhye

Novartis Pharmaceuticals

Chief Medical Officer since 2021

MD